BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.


The introduction of tyrosine kinase inhibitors (TKIs), starting with imatinib and followed by second and third generation TKIs, has significantly changed the clinical management of patients with chronic myeloid leukemia (CML). Despite their unprecedented clinical success, a proportion of patients fail to achieve complete cytogenetic remission by 12 months of treatment (primary resistance) while others experience progressive resistance after an initial response (secondary resistance). BCR-ABL1 kinase domain (KD) mutations have been detected in a proportion of patients at the time of treatment failure, and therefore their identification and monitoring plays an important role in therapeutic decisions particularly when switching TKIs. When monitoring KD mutations in a clinical laboratory, the choice of method should take into account turnaround time, cost, sensitivity, specificity, and ability to accurately quantify the size of the mutant clone. In this article, we describe in a "manual" style the methods most widely used in our laboratory to monitor KD mutations in patients with CML including direct sequencing, D-HPLC, and pyrosequencing. Advantages, disadvantages, interpretation of results, and their clinical applications are reviewed for each method.

DOI: 10.1002/ajh.22272
Citations per Year

Citation Velocity: 6

Averaging 6 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Alikian2012BCRABL1KD, title={BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.}, author={Mary Alikian and Gareth Gerrard and Papagudi Ganesan Subramanian and Katherine Mudge and Pierre Foskett and Jamshid S Khorashad and Ai Chiin Lim and David F. Marin and Dragana Milojkovic and Alistair Reid and Katy Rezvani and John M . Goldman and Jane F. Apperley and Letizia Foroni}, journal={American journal of hematology}, year={2012}, volume={87 3}, pages={298-304} }